Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 11/20 | 0.62 |
| ▸ | ACE | P12821 | 9/20 | 0.62 |
| ▸ | MMEL1 | Q495T6 | 2/20 | 0.55 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.54 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.53 |
| ▸ | PSAT1 | Q9Y617 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8522676 | 1.00 | MME (0.62) | MMEACEMMEL1GPR88SRR | |
| SCHEMBL2706785 | 1.00 | MME (0.62) | MMEACEMMEL1GPR88SRR | |
| SCHEMBL8198670 | 1.00 | MME (0.62) | MMEACEMMEL1GPR88SRR | |
| SCHEMBL20580875 | 1.00 | MME (0.62) | MMEACEMMEL1GPR88SRR | |
| Hydrochloric Acid SCHEMBL2707341 | 0.98 | MME (0.64) | MMEACEMMEL1GPR88SRR | |
| Hydrochloric Acid SCHEMBL4441570 | 0.98 | MME (0.64) | MMEACEMMEL1GPR88SRR | |
| Hydrochloric Acid SCHEMBL29202155 | 0.98 | MME (0.64) | MMEACEMMEL1GPR88SRR | |
| Bromide SCHEMBL598837 | 0.98 | MME (0.60) | MMEACEMMEL1GPR88SRR | |
| Hydrochloric Acid SCHEMBL597864 | 0.98 | MME (0.64) | MMEACEMMEL1GPR88SRR | |
| Hypochlorous Acid SCHEMBL20836627 | 0.97 | MME (0.59) | MMEACEMMEL1GPR88SRR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118812371-A | Synthesis method of (2R, 4S) -5- ([ 1,1' -biphenyl ] -4-yl) -4-amino-2-methyl pentanoic acid | 杭州科巢生物科技有限公司 | 2024-10-22 | — | — | CN | claimed |
| CN-118109528-A | Method for biocatalytically synthesizing Sha Kuba- ([ 1,1' -biphenyl ] -4-yl) -4-amino-2-methyl pentanoic acid serving as Sha Kuba yeast intermediate | 江苏海洋大学 | 2024-05-31 | — | — | CN | claimed |
| CN-115772509-A | Transaminase mutant and coding gene and application thereof | 广东东阳光药业有限公司 | 2023-03-10 | — | — | CN | claimed |
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | claimed |
| CN-110845349-B | Purification method of Sacubitril valsartan sodium intermediate | 株洲千金药业股份有限公司 | 2020-11-24 | — | — | CN | claimed |
| CN-111265518-A | Composition containing a mixture of biphenyl derivatives and uses thereof | 黄泳华 | 2020-06-12 | — | — | CN | claimed |
| CN-110845349-A | Purification method of Sacubitril valsartan sodium intermediate | 株洲千金药业股份有限公司 | 2020-02-28 | — | — | CN | claimed |
| CN-110818581-A | Post-treatment method of Sacubitril valsartan sodium intermediate | 株洲千金药业股份有限公司 | 2020-02-21 | — | — | CN | claimed |
| US-20250250550-A1 | ENGINEERED TRANSAMINASE POLYPEPTIDES FOR INDUSTRIAL BIOCATALYSIS | CODEXIS INC (US) | 2025-08-07 | — | — | US | disclosed |
| US-12297462-B2 | Engineered transaminase polypeptides for industrial biocatalysis | CODEXIS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| CN-119371367-A | Preparation method of sakubi-qu intermediate | 山西库邦生物医药科技有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-118812371-A | Synthesis method of (2R, 4S) -5- ([ 1,1' -biphenyl ] -4-yl) -4-amino-2-methyl pentanoic acid | 杭州科巢生物科技有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118812371-A | Synthesis method of (2R, 4S) -5- ([ 1,1' -biphenyl ] -4-yl) -4-amino-2-methyl pentanoic acid | 杭州科巢生物科技有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118812371-A | Synthesis method of (2R, 4S) -5- ([ 1,1' -biphenyl ] -4-yl) -4-amino-2-methyl pentanoic acid | 杭州科巢生物科技有限公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-8115016-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-8115016-B2 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-05-06 | — | — | US | disclosed |
| WO-2008083967-A2 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | NOVARTIS AG (CH) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113801-A1 | Process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid | MME, REN, PAH | MME 1/4885ACE 14/4885MMEL1 444/4885 |
| US-20120142916-A1 | PROCESS FOR PREPARING 5-BIPHENYL-4-AMINO-2-METHYL PENTANOIC ACID | MME, REN, PAH | MME 1/4885ACE 14/4885MMEL1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.